Data to four years, in a phase II trial with the product in oral research of Genzyme Gauchers disease, suggests a significant improvement in all indicators.
Data to four years, in a phase II trial with the product in oral research of Genzyme Gaucher’s disease, suggests a significant improvement in all indicators. has already completed the recruitment in phase III of eliglustat tartrate trials. Cambridge (EE.)(UU.), February 2012.- Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), has presented the monitoring data to four years of the patients included in the clinical phase II trial of its oral product, in development for type I Gaucher disease, known as eliglustat tartrate. Maintained or additional improvements in all the goals, including markers of bone disease to four years were. The results have been presented for the first time at the Symposium Lysosomal Disease Network WORLD ”, held in San Diego (EE.)(UU.) Tartrate eliglustat, in the form of Tablet for oral administration, is under development in order to offer a more comfortable treatment alternative for adult patients with Gauchers Disease Type I, in addition to expanding treatment options to achieve individualized clinical objectives. The enzyme replacement therapy, which is administered via intravenous infusion, is currently the best treatment available for patients with Gauchers Disease Type I. Genzyme has already announced that the phase II trial, of 52 weeks duration, with eliglustat tartrate had complied with its primary objective, seeking a clinically significant response in at least two of the three primary objectives (improvements in the size of the...
Read More